“If you're going to try to embrace new worlds, you must try to embrace new ideas."

genetic heart diseases

genetic heart diseases

genetic heart diseases

genetic heart diseases

SEO related. Do not remove this box.
Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives. 
Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines. 

Latest News

Phlox Therapeutics Secures New Funding to Advance RNA Therapies for Genetic Cardiomyopathies

Phlox Therapeutics raises 1.9M funding to develop RNA therapies for genetic laminopathies The investor syndicate includes ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures and UHSF Funds support preclinical development of Phox’s lead program Naarden, The Netherlands, 6 November 2024 – Phlox Therapeutics (“Phlox”), a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, […]
continue reading

Phlox Therapeutics Raises Additional Seed Funding to Further Develop RNA Therapies for Genetic Laminopathies

Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]
continue reading

Investors

logo image of F1RST Biogeneration Ventures

Team

Prof. dr. Yigal Pinto

Founder and CMO

Margien Boels

Director of Operations

Prof. dr. Eva Van Rooij

Founder and CSO

Rianne Ellenbroek

Non-executive director

Ross Gordon 

Observer

“If you're going to try to embrace new worlds, you must try to embrace new ideas."

Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives. 

Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines.

Latest news

Phlox Therapeutics Secures New Funding to Advance RNA Therapies for Genetic Cardiomyopathies

Phlox Therapeutics raises 1.9M funding to develop RNA therapies for genetic laminopathies The investor syndicate includes ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures and UHSF Funds support preclinical development of Phox’s lead program Naarden, The Netherlands, 6 November 2024 – Phlox Therapeutics (“Phlox”), a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, […]
continue reading

Phlox Therapeutics Raises Additional Seed Funding to Further Develop RNA Therapies for Genetic Laminopathies

Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]
continue reading

Investors

logo image of F1RST Biogeneration Ventures

Team

Prof. dr. Yigal Pinto
Founder and CMO
Margien Boels
Director of Operations
Prof. dr. Eva Van Rooij
Founder and CSO
Rianne Ellenbroek
Non-executive director
Ros Gordon
Observer